• Je něco špatně v tomto záznamu ?

Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer

I. Kolarova, J. Vanasek, K. Odrazka, B. Melichar, A. Ryska, J. Petera, M. Vosmik, M. Dolezel

. 2019 ; 163 (4) : 285-292. [pub] 20191211

Jazyk angličtina Země Česko

Typ dokumentu srovnávací studie, časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20010309

Breast cancer with high expression of human epidermal growth factor receptor (HER)-2 represents a biologically and clinically heterogeneous group of neoplastic disorders. Importantly, hormone receptor expression has an effect on biological properties and affects the selection of therapies. On the basis of molecular genetics, four principal subtypes, including luminal A, luminal B, HER2-enriched (HER-2-E), and basal-like can be distinguished. Breast tumors characterized by HER-2 positivity and simultaneous expression of hormone receptors, triple positive breast cancers (TPBC) are of increasing interest owing to the unique biological characteristics associated with complex interactions between HER-2 and hormone receptor signaling pathways. Interactions between hormone receptors and HER-2 explain the decreased efficacy of hormonal therapy in comparison with HER-2-negative patients. The expression of estrogen receptors in HER-2 positive tumors may also be associated with resistance to anti-HER-2 treatment. Multiple available therapeutic options, including hormonal therapy, anti-HER-2 agents and cytotoxic drugs explain favorable prognosis of TPBC. Escalation and de-escalation therapeutic strategies that could result in lower toxicities are being investigated as well as combinations of anti-HER-2 agents with hormonal therapy, immunotherapy, cyclin dependent kinase 4/6 and phosphatidyl inositol-3-kinase inhibitors. Distinction between subtypes of HER-2-positive breast cancer and treatment diversification may result in improved outcomes in TPBC. A response to neoadjuvant therapy may serve in the tailoring of therapy management.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20010309
003      
CZ-PrNML
005      
20200720150810.0
007      
ta
008      
200707s2019 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2019.060 $2 doi
035    __
$a (PubMed)31831888
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Kolářová, Iveta $7 xx0110482 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic; Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic
245    10
$a Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer / $c I. Kolarova, J. Vanasek, K. Odrazka, B. Melichar, A. Ryska, J. Petera, M. Vosmik, M. Dolezel
504    __
$a Literatura
520    9_
$a Breast cancer with high expression of human epidermal growth factor receptor (HER)-2 represents a biologically and clinically heterogeneous group of neoplastic disorders. Importantly, hormone receptor expression has an effect on biological properties and affects the selection of therapies. On the basis of molecular genetics, four principal subtypes, including luminal A, luminal B, HER2-enriched (HER-2-E), and basal-like can be distinguished. Breast tumors characterized by HER-2 positivity and simultaneous expression of hormone receptors, triple positive breast cancers (TPBC) are of increasing interest owing to the unique biological characteristics associated with complex interactions between HER-2 and hormone receptor signaling pathways. Interactions between hormone receptors and HER-2 explain the decreased efficacy of hormonal therapy in comparison with HER-2-negative patients. The expression of estrogen receptors in HER-2 positive tumors may also be associated with resistance to anti-HER-2 treatment. Multiple available therapeutic options, including hormonal therapy, anti-HER-2 agents and cytotoxic drugs explain favorable prognosis of TPBC. Escalation and de-escalation therapeutic strategies that could result in lower toxicities are being investigated as well as combinations of anti-HER-2 agents with hormonal therapy, immunotherapy, cyclin dependent kinase 4/6 and phosphatidyl inositol-3-kinase inhibitors. Distinction between subtypes of HER-2-positive breast cancer and treatment diversification may result in improved outcomes in TPBC. A response to neoadjuvant therapy may serve in the tailoring of therapy management.
650    _2
$a dospělí $7 D000328
650    _2
$a hormonální protinádorové látky $x aplikace a dávkování $7 D018931
650    _2
$a protinádorové látky imunologicky aktivní $7 D000074322
650    _2
$a nádory prsu $x genetika $x mortalita $x patologie $x terapie $7 D001943
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mastektomie $x metody $7 D008408
650    _2
$a lidé středního věku $7 D008875
650    _2
$a invazivní růst nádoru $x patologie $7 D009361
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a chinoliny $x terapeutické užití $7 D011804
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a receptor erbB-2 $x genetika $7 D018719
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a analýza přežití $7 D016019
650    _2
$a trastuzumab $x terapeutické užití $7 D000068878
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Vaňásek, Jaroslav, $d 1952- $7 nlk19990073982 $u Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic; Oncology Centre, Multiscan, Pardubice, Czech Republic; Department of Clinical and Radiation Oncology, Pardubice Hospital, Pardubice, Czech Republic
700    1_
$a Odrážka, Karel $7 mzk2002148290 $u Oncology Centre, Multiscan, Pardubice, Czech Republic; Department of Clinical and Radiation Oncology, Pardubice Hospital, Pardubice, Czech Republic; Department of Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Postgraduate Medical Education, Prague, Czech Republic
700    1_
$a Melichar, Bohuslav, $d 1965- $7 skuk0000853 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic; Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic; Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic
700    1_
$a Ryška, Aleš, $d 1970- $7 nlk20020124969 $u The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital Hradec Kralove, Czech Republic
700    1_
$a Petera, Jiří, $d 1959- $7 xx0000229 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic; Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic
700    1_
$a Vošmik, Milan, $d 1972- $7 xx0135408 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic; Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic
700    1_
$a Doležel, Martin $7 xx0075943 $u Department of Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 163, č. 4 (2019), s. 285-292
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31831888 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20200707 $b ABA008
991    __
$a 20200716100648 $b ABA008
999    __
$a ok $b bmc $g 1545950 $s 1100401
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 163 $c 4 $d 285-292 $e 20191211 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20200707

Najít záznam

Citační ukazatele

Možnosti archivace